RE:RE:2 year CR?I know a few competitor numbers:
Adstiladrin
24 month CR = 4% N803/Anktiva plus BCG
18 months CR = 33% In 6 months the N803/Anktiva plus BCG
24 month CR rate could drop 12% to
21% I say this because their 45% 12 month CR rate dropped to 33% at 18 months
In the
35 patient CORE-001 trial of
Cretostimogene plus Keytruda the
24 monthe CR rate was 46% Most of the 35 patienta received 21 treatments in the first 18 months of treatment and were subject to all of the side effects produced by Keytruda. It remains to be seen how long patients would maintain their CR if the treatments stopped.
(Cretostimogene induction was given as 6 weekly intravesical instillations followed by 3 weekly maintenance doses at months 3, 6, 9, 12, and 18. Pembrolizumab was administered for up to 24 mo.) https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4601 DJDawg wrote:
Eog is the best to confirm how many have reached 2 yrs out.
On that subject Eog, can you confirm what the best competitor numbers are so far for 2 yr data. What is the percent to beat?
I realize that with many of the competitors patients are getting ongoing "maintenance" so any CR data is hard to compare with our 1-2 and done approach.